D-0185-2025 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0185-2025 was initiated by Eugia US LLC on Dec 18, 2024 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: 19872 vials.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2025
Initiation Date
Dec 18, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
19872 vials

Product description

medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: Eugia US LLC, NJ 08520 NDC 55150-329-01 Shipper label: medroxyPROGESTERone Acetate Injectable Suspension, USP, 150 mg per mL, Distributed by: Eugia US LLC, NJ, Manufactured by: Eugia Pharma Specialties Limited, India

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide in the US

Code information

Lot No.: 1MP24069, Exp.: 08/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0185-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0185-2025. Report a data issue: hello@regdatalab.com.